Notice: This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VLON vs. RIGL, HRTX, ATXS, CMPS, VSTM, ESPR, EBS, RAPP, PHAT, and MBXShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Heron Therapeutics (HRTX), Astria Therapeutics (ATXS), COMPASS Pathways (CMPS), Verastem (VSTM), Esperion Therapeutics (ESPR), Emergent BioSolutions (EBS), Rapport Therapeutics (RAPP), Phathom Pharmaceuticals (PHAT), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical preparations" industry. Vallon Pharmaceuticals vs. Rigel Pharmaceuticals Heron Therapeutics Astria Therapeutics COMPASS Pathways Verastem Esperion Therapeutics Emergent BioSolutions Rapport Therapeutics Phathom Pharmaceuticals MBX Biosciences Rigel Pharmaceuticals (NASDAQ:RIGL) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Which has more volatility & risk, RIGL or VLON? Rigel Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Vallon Pharmaceuticals has a beta of -1.14, indicating that its stock price is 214% less volatile than the S&P 500. Which has stronger earnings & valuation, RIGL or VLON? Vallon Pharmaceuticals has lower revenue, but higher earnings than Rigel Pharmaceuticals. Vallon Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$179.28M2.04-$25.09M$0.9421.75Vallon Pharmaceuticals$100K829.14-$7.02M-$0.78-7.88 Do insiders and institutionals hold more shares of RIGL or VLON? 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.7% of Vallon Pharmaceuticals shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 37.3% of Vallon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer RIGL or VLON? In the previous week, Rigel Pharmaceuticals had 47 more articles in the media than Vallon Pharmaceuticals. MarketBeat recorded 47 mentions for Rigel Pharmaceuticals and 0 mentions for Vallon Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.69 beat Vallon Pharmaceuticals' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Rigel Pharmaceuticals Positive Vallon Pharmaceuticals Neutral Does the MarketBeat Community believe in RIGL or VLON? Rigel Pharmaceuticals received 466 more outperform votes than Vallon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Vallon Pharmaceuticals an outperform vote while only 68.98% of users gave Rigel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRigel PharmaceuticalsOutperform Votes46768.98% Underperform Votes21031.02% Vallon PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Do analysts recommend RIGL or VLON? Rigel Pharmaceuticals presently has a consensus target price of $36.80, suggesting a potential upside of 79.98%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Vallon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Vallon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is RIGL or VLON more profitable? Rigel Pharmaceuticals has a net margin of 2.46% compared to Vallon Pharmaceuticals' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of -14.80% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals2.46% -14.80% 3.03% Vallon Pharmaceuticals N/A -230.48%-124.89% SummaryRigel Pharmaceuticals beats Vallon Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Remove Ads Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.91M$6.94B$5.63B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E Ratio-7.886.1823.8818.99Price / Sales829.14226.35381.87119.49Price / CashN/A65.6738.0534.64Price / Book34.176.656.904.26Net Income-$7.02M$139.77M$3.19B$246.88M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$6.15-5.2%N/A+639.2%$82.91M$100,000.00-7.883Gap DownRIGLRigel Pharmaceuticals2.9203 of 5 stars$19.53-4.8%$36.80+88.4%+29.1%$348.86M$179.28M139.51160HRTXHeron Therapeutics3.7617 of 5 stars$2.22-7.1%$5.67+155.3%-5.0%$338.17M$144.29M-12.33300ATXSAstria Therapeutics1.5859 of 5 stars$5.82-6.0%$25.67+341.0%-55.5%$328.45MN/A-2.7830Earnings ReportAnalyst ForecastNews CoverageCMPSCOMPASS Pathways1.793 of 5 stars$3.54-5.3%$21.83+516.8%-66.3%$328.06MN/A-1.61120High Trading VolumeVSTMVerastem2.9812 of 5 stars$7.12+1.7%$13.63+91.4%-37.5%$316.89M$10M-2.2350Upcoming EarningsNews CoverageESPREsperion Therapeutics4.0559 of 5 stars$1.58-6.5%$6.75+327.2%-26.9%$311.32M$332.31M-2.47200Gap DownEBSEmergent BioSolutions4.0791 of 5 stars$5.66-2.0%$14.33+153.5%+97.0%$307.28M$1.01B-1.381,600Gap UpRAPPRapport Therapeutics1.3023 of 5 stars$8.27-3.7%$35.00+323.2%N/A$302.48MN/A0.00N/AUpcoming EarningsNews CoverageGap UpHigh Trading VolumePHATPhathom Pharmaceuticals3.5881 of 5 stars$4.40-13.0%$22.17+403.8%-42.0%$300.86M$55.25M-0.77110Analyst ForecastMBXMBX Biosciences1.9804 of 5 stars$8.98-9.2%$37.25+314.8%N/A$300.09MN/A0.0036Lockup ExpirationGap Down Remove Ads Related Companies and Tools Related Companies RIGL Alternatives HRTX Alternatives ATXS Alternatives CMPS Alternatives VSTM Alternatives ESPR Alternatives EBS Alternatives RAPP Alternatives PHAT Alternatives MBX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VLON) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
